title: Therapy for hormone-resistant prostate cancer: no longer a myth.
abstract: In conclusion, there have been impressive efforts to identify new cellular targets for the treatment of hormone-refractory disease. It appears that in some cases, survival may be extended; however, further prospective trials are necessary to confirm these observations.
authors.forename: D P
authors.initials: DP
authors.lastname: Petrylak
authors.forename: B
authors.initials: B
authors.lastname: Abi-Rashid
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D004961:Estramustine / Q000008:administration & dosage; D006801:Humans; D007654:Ketoconazole / Q000008:administration & dosage; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013498:Suramin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004961:Estramustine; D013498:Suramin; D007654:Ketoconazole